Stumble For Vical/Astellas CMV Vaccine In Kidney Transplants
Vical and Astellas have unveiled disappointing topline Phase II results with their cytomegalovirus vaccine in kidney transplant patients, although the product remains on track in the hematopoietic cell transplant setting.
You may also be interested in...
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.
Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.